KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Gross Margin (2019 - 2025)

Esperion Therapeutics' Gross Margin history spans 7 years, with the latest figure at 52.71% for Q3 2025.

  • For Q3 2025, Gross Margin fell 1381.0% year-over-year to 52.71%; the TTM value through Sep 2025 reached 58.2%, down 2338.0%, while the annual FY2024 figure was 79.36%, 1655.0% up from the prior year.
  • Gross Margin reached 52.71% in Q3 2025 per ESPR's latest filing, down from 65.35% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 95.57% in Q2 2021 to a low of 51.3% in Q2 2022.
  • Average Gross Margin over 5 years is 67.38%, with a median of 65.35% recorded in 2025.
  • Peak YoY movement for Gross Margin: tumbled -4428bps in 2022, then soared 4058bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 67.05% in 2021, then grew by 16bps to 77.89% in 2022, then decreased by -17bps to 64.49% in 2023, then decreased by -2bps to 62.91% in 2024, then decreased by -16bps to 52.71% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Gross Margin are 52.71% (Q3 2025), 65.35% (Q2 2025), and 51.48% (Q1 2025).